Meeting
2017 ASCO Annual Meeting
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
Authors
Joop De Langen
VU University Medical Center, Amsterdan, Netherlands
Joop De Langen , Justine Leonie Kuiper , Erik Thunnissen , Sayed MS Hashemi , Kim Monkhorst , Egbert F. Smit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02226757
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9042)
DOI
10.1200/JCO.2017.35.15_suppl.9042
Abstract #
9042
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.
First Author: Hiroe Kayatani
Poster
2019 ASCO Annual Meeting
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
First Author: Caicun Zhou
Poster
2012 ASCO Annual Meeting
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy.
First Author: Martin H. Schuler